• The company has simplified the testing of PAD, which is a marker for increased risk of stroke and cardiovascular disease.
• It runs on a capital light, license fee business model that generates high margins and substantial cash flows.
• The pandemic has interrupted the progress, but the company seems well placed to weather the storm.

Source: Semler Scientific: A Little Gem Of A Company (OTCMKTS:SMLR) | Seeking Alpha